SCHEMBL2857794

SCHEMBL2857794

CCc1cc(C(O)CC)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.39
LMNA P02545 2/20 0.39
CYP3A4 P08684 2/20 0.39
ALDH1A1 P00352 1/20 0.39
ADRB2 P07550 4/20 0.38
DRD2 P14416 1/20 0.37
NFKB1 P19838 3/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
ADRB1 P08588 1/20 0.35
PMP22 Q01453 2/20 0.35
BLM P54132 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
PDE4D Q08499 3/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15004196 0.84 DRD2 (0.47) HIF1ACYP3A4DRD2NFKB1TSHR
SCHEMBL5529209 0.78 NFKB1 (0.51) HIF1ALMNACYP3A4ALDH1A1ADRB2
SCHEMBL5522770 0.78 NFKB1 (0.51) HIF1ALMNACYP3A4ALDH1A1ADRB2
SCHEMBL5529736 0.78 NFKB1 (0.51) HIF1ALMNACYP3A4ALDH1A1ADRB2
SCHEMBL5521929 0.77 NFKB1 (0.42) HIF1ALMNACYP3A4ADRB2DRD2
SCHEMBL2863699 0.76 MEN1 (0.40) DRD2TSHRTDP1SMN1; SMN2
SCHEMBL7301978 0.76 LMNA (0.44) LMNA
SCHEMBL7047139 0.75 BACE1 (0.33) HIF1AADRB2DRD2NFKB1TSHR
SCHEMBL15514887 0.75 DRD2 (0.38) ALDH1A1DRD2TSHR
SCHEMBL5528364 0.75 ALDH1A1 (0.44) HIF1ALMNACYP3A4ALDH1A1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US claimed
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR HIF1A 1432/4885LMNA 2638/4885CYP3A4 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.